Administer the following premedications prior to SARCLISA infusion to reduce the risk and severity of IRRs.
The above recommended dose of dexamethasone (orally or IV) corresponds to the total dose to be administered only once before infusion as part of the premedication and of the backbone treatment, before SARCLISA and pomalidomide administration.
Administer the recommended premedication agents 15 to 60 minutes prior to starting a SARCLISA infusion.
Incremental escalation of the infusion rate should be considered only in the absence of IRRs.
75-minute infusion time starting after the second infusion in the absence of IRRs1
SARCLISA Dosing Guide
For detailed dosing and administration information, download the PDF now
Administration adjustments should be made if patients experience the following adverse reactions.
No dose reduction of SARCLISA is recommended
SARCLISA, an anti-CD38 antibody, may interfere with blood bank serological tests with false-positive reactions in indirect antiglobulin tests (indirect Coombs tests), antibody detection (screening) tests, antibody identification panels, and antihuman globulin crossmatches in patients treated with SARCLISA.
Provide this document to your patients so they can easily inform other HCPs that they are receiving SARCLISA if they need to receive a blood transfusion
Storage and Handling Flashcard
A quick reference tool for SARCLISA storage and handling information